In addition, PDCD1 demonstrated a very high positive correlation with sensitivity in docetaxel, suggesting that this drug could be used successfully to treat cancer, alone or in combination with ICIs like pembrolizumab and nivolumab. This evidence concerns the gene PDCD1 and cancer.